Literature DB >> 25618577

Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography.

Hayato Tada1, Masa-aki Kawashiri2, Hirofumi Okada2, Ryota Teramoto2, Tetsuo Konno2, Tsuyoshi Yoshimuta2, Kenji Sakata2, Atsushi Nohara3, Akihiro Inazu4, Junji Kobayashi5, Hiroshi Mabuchi3, Masakazu Yamagishi2, Kenshi Hayashi2.   

Abstract

The aims of this study were (1) to determine whether the accumulation of coronary plaque burden assessed with coronary computed tomography angiography (CCTA) can predict future events and (2) to estimate the onset and progression of coronary atherosclerosis in patients with familial hypercholesterolemia (FH). Consecutive 101 Japanese patients with heterozygous FH (men = 52, mean age 56 ± 16 years, mean low-density lipoprotein cholesterol 264 ± 58 mg/dl) who underwent 64-detector row CCTA without known coronary artery disease were retrospectively evaluated by assigning a score (0 to 5) to each of 17 coronary artery segments according to the Society of Cardiovascular Computed Tomography guidelines. Those scores were summed and subsequently natural log transformed. The periods to major adverse cardiac events (MACE) were estimated using multivariable Cox proportional hazards models. During the follow-up period (median 941 days), 21 MACE had occurred. Receiver operating characteristic curve analyses identified a plaque burden score of 3.35 (raw score 28.5) as the optimal cutoff for predicting a worse prognosis. Multivariate Cox regression analysis identified the presence of a plaque score ≥3.35 as a significant independent predictor of MACE (hazard ratio = 3.65; 95% confidence interval 1.32 to 25.84, p <0.05). The regression equations were Y = 0.68X - 15.6 (r = 0.54, p <0.05) in male and Y = 0.74X - 24.8 (r = 0.69, p <0.05) in female patients with heterozygous FH. In conclusion, coronary plaque burden identified in a noninvasive, quantitative manner was significantly associated with future coronary events in Japanese patients with heterozygous FH and that coronary atherosclerosis may start to develop, on average, at age 23 and 34 years in male and female patients with heterozygous FH, respectively.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25618577     DOI: 10.1016/j.amjcard.2014.12.034

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

1.  Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre.

Authors:  Agnieszka Mickiewicz; Justyna Borowiec-Wolna; Witold Bachorski; Natasza Gilis-Malinowska; Rafał Gałąska; Grzegorz Raczak; Magdalena Chmara; Bartosz Wasąg; Miłosz J Jaguszewski; Marcin Fijałkowski; Marcin Gruchała
Journal:  Cardiol J       Date:  2018-09-20       Impact factor: 2.737

Review 2.  Updates on the Use of Subclinical Atherosclerosis to Predict Risk of Cardiovascular Events in Heterozygous Familial Hypercholesterolemia.

Authors:  Antonio Gallo; Reed Mszar; Marcio Hiroshi Miname
Journal:  Curr Atheroscler Rep       Date:  2022-04-07       Impact factor: 5.113

Review 3.  Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care.

Authors:  Gerald F Watts; Samuel S Gidding; Pedro Mata; Jing Pang; David R Sullivan; Shizuya Yamashita; Frederick J Raal; Raul D Santos; Kausik K Ray
Journal:  Nat Rev Cardiol       Date:  2020-01-23       Impact factor: 32.419

Review 4.  Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors.

Authors:  Ivan Pećin; Merel L Hartgers; G Kees Hovingh; Ricardo Dent; Željko Reiner
Journal:  Eur J Prev Cardiol       Date:  2017-06-23       Impact factor: 7.804

Review 5.  Low-Density Lipoprotein Cholesterol Level cannot be too Low: Considerations from Clinical Trials, Human Genetics, and Biology.

Authors:  Hayato Tada; Soichiro Usui; Kenji Sakata; Masayuki Takamura; Masa-Aki Kawashiri
Journal:  J Atheroscler Thromb       Date:  2020-04-30       Impact factor: 4.928

6.  Aortic Root Calcification Score as an Independent Factor for Predicting Major Adverse Cardiac Events in Familial Hypercholesterolemia.

Authors:  Hirofumi Okada; Hayato Tada; Kenshi Hayashi; Hiroki Kawashima; Tadanori Takata; Kenji Sakata; Atsushi Nohara; Hiroshi Mabuchi; Masakazu Yamagishi; Masa-Aki Kawashiri
Journal:  J Atheroscler Thromb       Date:  2018-01-10       Impact factor: 4.928

Review 7.  Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters.

Authors:  Alpo Vuorio; Petri T Kovanen
Journal:  Nutrients       Date:  2018-12-01       Impact factor: 5.717

8.  Clinical Impact of Carotid Plaque Score rather than Carotid Intima-Media Thickness on Recurrence of Atherosclerotic Cardiovascular Disease Events.

Authors:  Hayato Tada; Tamami Nakagawa; Hirofumi Okada; Takuya Nakahashi; Mika Mori; Kenji Sakata; Atsushi Nohara; Masayuki Takamura; Masa-Aki Kawashiri
Journal:  J Atheroscler Thromb       Date:  2019-05-18       Impact factor: 4.928

9.  Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia.

Authors:  Alpo Vuorio; Petri T Kovanen
Journal:  J Clin Lipidol       Date:  2020-06-15       Impact factor: 4.766

10.  Comment on: "Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry".

Authors:  Alpo Vuorio; Petri T Kovanen
Journal:  Drugs       Date:  2021-05-28       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.